Oric Pharmaceuticals (ORIC) Projected to Post Quarterly Earnings on Monday

Oric Pharmaceuticals (NASDAQ:ORIC) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($0.46) per share for the quarter.

Oric Pharmaceuticals Price Performance

ORIC opened at $9.24 on Friday. The business’s 50-day moving average price is $10.23 and its two-hundred day moving average price is $8.13. Oric Pharmaceuticals has a 1 year low of $3.90 and a 1 year high of $14.67. The company has a market capitalization of $787.43 million, a price-to-earnings ratio of -4.94 and a beta of 1.69.

Insider Activity

In related news, Director Angie You acquired 26,597 shares of the firm’s stock in a transaction dated Friday, June 20th. The stock was bought at an average price of $9.39 per share, for a total transaction of $249,745.83. Following the acquisition, the director directly owned 26,597 shares of the company’s stock, valued at approximately $249,745.83. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Dominic Piscitelli sold 32,466 shares of Oric Pharmaceuticals stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $10.50, for a total value of $340,893.00. Following the transaction, the chief financial officer owned 68,317 shares of the company’s stock, valued at $717,328.50. The trade was a 32.21% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 40,000 shares of company stock valued at $416,289 in the last 90 days. 6.82% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Oric Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Creative Planning bought a new position in Oric Pharmaceuticals during the second quarter worth about $113,000. Jane Street Group LLC grew its holdings in Oric Pharmaceuticals by 56.0% during the first quarter. Jane Street Group LLC now owns 31,198 shares of the company’s stock worth $174,000 after purchasing an additional 11,198 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Oric Pharmaceuticals by 8.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company’s stock worth $226,000 after purchasing an additional 3,131 shares during the period. AQR Capital Management LLC bought a new position in Oric Pharmaceuticals during the first quarter worth about $276,000. Finally, Goldman Sachs Group Inc. grew its holdings in Oric Pharmaceuticals by 9.2% during the first quarter. Goldman Sachs Group Inc. now owns 294,784 shares of the company’s stock worth $1,645,000 after purchasing an additional 24,778 shares during the period. Institutional investors own 95.05% of the company’s stock.

Analysts Set New Price Targets

ORIC has been the topic of several recent research reports. Oppenheimer dropped their price target on Oric Pharmaceuticals from $15.00 to $12.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 6th. Cantor Fitzgerald reissued an “overweight” rating on shares of Oric Pharmaceuticals in a research note on Tuesday, May 6th. Wedbush restated an “outperform” rating and issued a $20.00 price objective on shares of Oric Pharmaceuticals in a report on Monday, June 23rd. LADENBURG THALM/SH SH started coverage on Oric Pharmaceuticals in a report on Tuesday, July 8th. They issued a “buy” rating and a $15.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and issued a $21.00 price objective on shares of Oric Pharmaceuticals in a report on Monday, May 5th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $18.57.

Oric Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.